1

Intellia Therapeutics

#4505

Rank

$1.79B

Marketcap

US United States

Country

Intellia Therapeutics
Leadership team

Dr. John M. Leonard M.D. (Pres, CEO & Director)

Mr. Glenn G. Goddard CPA (Exec. VP, CFO & Treasurer)

Dr. Laura Sepp-Lorenzino Ph.D. (Exec. VP & Chief Scientific Officer)

Products/ Services
Biotechnology, Genetics, Health Care, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2014
Company Registration
SEC CIK number: 0001652130
Revenue
20M - 100M
Traded as
NTLA
Social Media
Overview
Location
Summary
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
History

Intellia was founded in 2014 by world-renowned scientists, including four of the inventors of CRISPR/Cas9. The company's mission is to enable precise and efficient therapeutic somatic gene editing to create curative medicines for serious diseases, initially focusing on liver diseases.

Mission
Developing curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
Vision
Intellia Therapeutics' vision is to become a fully integrated gene-editing biopharmaceutical company, advancing the healthcare of tomorrow by unlocking the full potential of CRISPR/Cas9.
Key Team

Mr. James E. Basta Esq., J.D. (Exec. VP, Gen. Counsel & Corp. Sec.)

Dr. David Lebwohl M.D. (Exec. VP & Chief Medical Officer)

Mr. Nessan Bermingham Ph.D. (Founder & Member of Scientific Advisor Board)

Dr. Jennifer A. Doudna Ph.D. (Founder & Member of Scientific Advisor Board)

Dr. Rachel E. Haurwitz Ph.D. (Co-Founder)

Dr. Andrew May (Founder and Member of Scientific Advisor Board)

Dr. Derrick J. Rossi Ph.D. (Founder & Member of Scientific Advisor Board)

Recognition and Awards
Intellia Therapeutics has been recognized with multiple awards including the 2019 Golden Biotech Award and the 2018 California Innovation Award. The company has also been named one of the World’s Most Innovative Companies by Fast Company in 2020.
References
Intellia Therapeutics
Leadership team

Dr. John M. Leonard M.D. (Pres, CEO & Director)

Mr. Glenn G. Goddard CPA (Exec. VP, CFO & Treasurer)

Dr. Laura Sepp-Lorenzino Ph.D. (Exec. VP & Chief Scientific Officer)

Products/ Services
Biotechnology, Genetics, Health Care, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2014
Company Registration
SEC CIK number: 0001652130
Revenue
20M - 100M
Traded as
NTLA
Social Media